Reported Reactions

Devices › Stimulator, autonomic nerve, implanted for epilepsy

Device brand name · Lyj

Bipol Lead Model 302: medical device reports filed with FDA

162 reports name it, 2006–2010. Manufacturer given most often on reports: Cyberonics. Product code LYJ.

162
device reports naming the brand
0% of all MAUDE reports · about 8 a year
0
reports, 12 months to August 2026
0 in the 12 months before
81.5%
classified as malfunction
58.7% across the product code
0%
classified as death, as reported
0 reports · not verified by FDA

162 medical device reports received by FDA name the brand "Bipol Lead Model 302" (lyj); the manufacturer given most often on reports is Cyberonics; received from August 2006 to December 2010. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.

0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (81.5%) and injury (18.5%); across all stimulator, autonomic nerve, implanted for epilepsy reports (product code LYJ) death is recorded in 5.6% and malfunction in 58.7%. Event type is the reporter's classification of the report, not a verified outcome.

The device problems coded most often are high impedance (57.4%), explanted (32.7%) and device remains implanted (32.1%). The patient problems coded most often are therapy/non-surgical treatment, additional, surgical procedure, repeated and seizures. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Reports by month, five years

No report naming Bipol Lead Model 302 was received in the five years to August 2026; the latest was received in December 2010.

By year received

045902006: 1020062007: 9020072008: 4920082009: 420092010: 92010

Event type and report source

Event type, as classified on the report

Death0%0
Injury18.5%30
Malfunction81.5%132
Other0%0
Not given0%0

Who filed the report

Manufacturer report100%162
Voluntary report0%0
User facility report0%0
Distributor report0%0
Not given0%0

Grey bar: all 52,004 reports carrying product code LYJ. Event type is the filer's classification and is not verified by FDA.

Device problems coded

Device problem (FDA code)ReportsShareShare across product code
High impedance9357.4%18.1%
Explanted5332.7%4.6%
Device remains implanted5232.1%4.9%
Replace3823.5%2.6%
Lead(s), breakage of127.4%0.6%
Breakthe device broke42.5%1.9%
Device issuea problem with the device42.5%0.6%
Lead(s), fracture of42.5%0.3%
Battery failure31.9%0.5%
Fracturea broken bone31.9%8.4%
Implant, removal of31.9%0.1%
Connection error21.2%0.1%
Detachment of device component21.2%0.3%
Dislodged21.2%0%
Implant extrusion21.2%0.2%
Loose21.2%0.1%
Malposition of device21.2%0.3%
Migration or expulsion of device21.2%1.1%
Bent10.6%0.2%
Component(s), worn10.6%0%

FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.

Patient problems coded

Patient problem (FDA code)ReportsShare
Therapy/non-surgical treatment, additional4930.2%
Surgical procedure, repeated4225.9%
Seizures2515.4%
Surgical procedure1811.1%
Therapeutic response, decreased127.4%
Paralysis116.8%
Painpain, site not specified106.2%
Hospitalization required84.9%
Swellingswelling53.1%
Treatment with medication(s)31.9%
Complaint, ill-defined21.2%
Erythemaskin redness21.2%
Foreign body, removal of21.2%
Improved patient condition21.2%
Muscle spasm(s)21.2%

Patient problem codes are present mainly in reports filed since 2019 and are often blank.

In context

MeasureBipol Lead Model 302Product code LYJAll MAUDE reports
Reports16252,00426,136,888
Share of that pool—0.3%0%
Classified as death, per 1,000 reports0569
Classified as injury18.5%35.5%36.2%
Classified as malfunction81.5%58.7%62.3%
Filed by the manufacturer100%99.5%94.9%

Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Other brands with product code LYJ

BrandReportsLatest 12 monthsClassified as death
Programming Software7,45310%
Lead Model 3027,2591360%
Pulse Gen Model 1025,9031412.2%
Pulse Gen Model 1034,518348.5%
Pulse Gen Model 1064,0231445.1%
Pulse Gen Model 10003,6015495.7%
Lead Model 3043,3292720.1%
Bipol Lead Model 3001,955120.1%
Pulse Gen Model Unk1,914713.6%
Ncp Pulse Generator1,272030%
Lead Model Unknown1,253461.6%
Pulse Gen Model 1011,210012.6%
Pulse Gen Model 1051,19176.7%
Vns Therapy Pulse1,064010.7%
Pulse Gen Model 102r985010.9%

Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."

Questions about Bipol Lead Model 302 reports

How many FDA reports name Bipol Lead Model 302?

162 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.

What kinds of events are reported?

malfunction (81.5%) and injury (18.5%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.

What device problems are coded?

high impedance (57.4%), explanted (32.7%), device remains implanted (32.1%), replace (23.5%) and lead(s), breakage of (7.4%). These are FDA's device problem codes as entered on the report.

Who files these reports?

manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.

Do these reports show that Bipol Lead Model 302 was at fault?

No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."

How do I report a problem with a medical device?

Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.